A female-specific role for trigeminal dynorphin in orofacial pain comorbidity

Pain. 2023 Dec 1;164(12):2801-2811. doi: 10.1097/j.pain.0000000000002980. Epub 2023 Jul 18.

Abstract

Migraine is commonly reported in patients with temporomandibular disorders (TMDs), but little is known about the mechanisms underlying the comorbid condition. Here, we prepared a mouse model to investigate this comorbidity, in which masseter muscle tendon ligation (MMTL) was performed to induce a myogenic TMD, and the pre-existing TMD enabled a subthreshold dose of nitroglycerin (NTG) to produce migraine-like pain in mice. RNA sequencing followed by real-time quantitative polymerase chain reaction confirmation showed that MMTL plus NTG treatment increased prodynorphin ( Pdyn ) mRNA expression in the spinal trigeminal nucleus caudalis (Sp5C) of female mice but not in male mice. Chemogenetic inhibition of Pdyn -expressing neurons or microinjection of antidynorphin antiserum in the Sp5C alleviated MMTL-induced masseter hypersensitivity and diminished the MMTL-enabled migraine-like pain in female mice but not in male mice. Moreover, chemogenetic activation of Pdyn -expressing neurons or microinjection of dynorphin A (1-17) peptide in the Sp5C enabled a subthreshold dose of NTG to induce migraine-like pain in female mice but not in male mice. Taken together, our results suggest that trigeminal dynorphin has a female-specific role in the modulation of comorbid TMDs and migraine.

MeSH terms

  • Animals
  • Comorbidity
  • Disease Models, Animal
  • Dynorphins*
  • Facial Pain
  • Female
  • Humans
  • Male
  • Mice
  • Migraine Disorders* / drug therapy
  • Nitroglycerin / pharmacology

Substances

  • Dynorphins
  • Nitroglycerin